EIDX - Eidos Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
39.59
+0.27 (+0.69%)
As of 12:08PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close39.32
Open39.40
Bid39.82 x 1000
Ask40.18 x 900
Day's Range37.90 - 40.17
52 Week Range9.57 - 49.72
Volume24,135
Avg. Volume174,900
Market Cap1.482B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.27
Earnings DateAug 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est47.86
Trade prices are not sourced from all markets
  • How this company is disrupting biotech with 30-somethings and industry vets
    American City Business Journals

    How this company is disrupting biotech with 30-somethings and industry vets

    Three young execs and a trio of experienced veterans are trying to move drugs attacking genetic diseases to market faster with a lean model.

  • Business Wire

    BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics

    BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced today that it was unable to come to an agreement with the Special Committee formed by its subsidiary Eidos Therapeutics (EIDX), a clinical-stage biopharmaceutical company developing AG10 for the treatment of transthyretin amyloidosis (ATTR), to acquire the outstanding common stock of Eidos that BridgeBio does not already own (approximately 34% of Eidos’s outstanding shares). Subsequent to an initial offer of 1.3 BridgeBio shares for each Eidos share, the offer was raised twice, resulting in a final offer equivalent to 1.5 BridgeBio shares for each Eidos share with an option for Eidos shareholders to receive a portion of that consideration in cash.

  • Alexion (ALXN) Collaborates With Stealth BioTherapeutics
    Zacks

    Alexion (ALXN) Collaborates With Stealth BioTherapeutics

    Alexion (ALXN) teams up with Stealth BioTherapeutics for a late-stage therapy for mitochondrial diseases.

  • GlobeNewswire

    Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy at the AHA 2019 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation

    SAN FRANCISCO, Sept. 30, 2019 -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet.

  • GlobeNewswire

    Eidos Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

    Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX) today announced that management will present at the 2019 Cantor Global Healthcare Conference on Thursday, October 3rd at 3:00 p.m. EDT in New York, NY. AG10 is an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin, or TTR, thereby halting at its outset the series of molecular events that give rise to TTR amyloidosis, or ATTR. In a Phase 2 clinical trial in patients with symptomatic ATTR-CM, AG10 was generally well tolerated, demonstrated greater than 90 percent average TTR stabilization at Day 28, and increased serum TTR concentrations, a prognostic indicator of survival in a retrospective study of ATTR-CM patients, in a dose-dependent manner.

  • Alexion (ALXN) Down on News of CFO Clancy's Departure in 2019
    Zacks

    Alexion (ALXN) Down on News of CFO Clancy's Departure in 2019

    Alexion's (ALXN) shares decline, following the news of the departure of its current chief financial officer, Paul Clancy.

  • Business Wire

    EIDOS THERAPEUTICS (EIDX) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Eidos Therapeutics, Inc. for Potential Securities Violations and Breach of Fiduciary Duty

    Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential securities violations and breach of fiduciary duty claims against Eidos Therapeutics, Inc.

  • Business Wire

    Eidos Therapeutics Special Committee Rejects Proposal from BridgeBio Pharma to Acquire Shares

    Eidos Therapeutics, Inc. (EIDX) (“Eidos”) announced today that the Special Committee of its Board of Directors (the “Special Committee”) unanimously rejected the non-binding proposal dated August 8, 2019 (the “Proposal”) from BridgeBio Pharma, Inc., the parent entity of the Company’s majority stockholder (“BridgeBio”), to purchase all of the outstanding common stock of the Company not already owned by BridgeBio for a fixed exchange ratio of 1.30 shares of BridgeBio common stock for each share of Eidos common stock.

  • Alexion (ALXN) In-licenses Amyloidosis Candidate In Japan
    Zacks

    Alexion (ALXN) In-licenses Amyloidosis Candidate In Japan

    Alexion (ALXN) strengthens its amyloidosis portfolio with an exclusive license secured from Eidos to develop and commercialize an investigational small molecule AG10 in Japan.

  • GlobeNewswire

    Kaskela Law LLC Announces Shareholder Investigation of Eidos Therapeutics, Inc. and Encourages Investors to Contact the Firm – EIDX

    PHILADELPHIA, Sept. 03, 2019 -- Kaskela Law LLC is investigating Eidos Therapeutics, Inc. (“Eidos”) (NASDAQ: EIDX) on behalf of the company’s shareholders.  The investigation.

  • 3 New Biotech Stocks That Keep On Soaring
    Motley Fool

    3 New Biotech Stocks That Keep On Soaring

    Can their share prices continue to climb?

  • Andreas Halvorsen's Top 5 Buys of the 2nd Quarter
    GuruFocus.com

    Andreas Halvorsen's Top 5 Buys of the 2nd Quarter

    Viking Global’s top buys include 3 IPOs Continue reading...

  • ACCESSWIRE

    Kaskela Law LLC Announces Shareholder Investigation of Eidos Therapeutics, Inc. - EIDX

    PHILADELPHIA, PA / ACCESSWIRE / August 14, 2019 / Kaskela Law LLC announces that it is investigating Eidos Therapeutics, Inc. (“Eidos” or the “Company”) (NASDAQ:EIDX) on behalf of the Company’s shareholders. ...

  • Benzinga

    The Daily Biotech Pulse: Vascepa Delay Sends Amarin Reeling, Eidos Jumps On Buyout Offer, Nektar's Bitter Q2

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 8) Aquinox Pharmaceuticals Inc (NASDAQ: AQXP ) Avedro Inc ...

  • GlobeNewswire

    Eidos Therapeutics Reports Second Quarter 2019 Financial Results

    SAN FRANCISCO, Aug. 01, 2019 -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX), today reported its financial results for the second quarter ended June 30, 2019 and provided an.

  • 3 Stocks Corporate Insiders are Buying Now
    TipRanks

    3 Stocks Corporate Insiders are Buying Now

    For investors, following insiders can be a viable trading strategy. Corporate officers, board members, and investment funds are indeed careful about the way they allocate funds, so following their purchase activity can lead to great investment tips. More importantly, these are the entities with a more direct knowledge of the companies and business sectors. And they put that knowledge to use when planning stock purchases.TipRanks offers the Insiders’ Hot Stocks, a data tool that tracks over 43,000 corporate insiders and reveals their latest moves. We’ve used it to find three affordably priced stocks that are showing positive insider signals. Looking for the stocks, we used the Major Event Strategy, the most successful of four filters available on TipRanks for sorting insider trades.Insider Trading Strategies Sinclair Broadcast Group, Inc. (SBGI)Sinclair is the largest TV operator in the US, reaching 40% of American households with 193 stations in 100 local markets. The network is focused mainly in the Midwest and South. TV, with its advertising reach, is a lucrative business and Sinclair generated revenues over $3 billion in FY2018.Executive Chairman David D. Smith, son of the company’s founder, made the most recent insider purchase of SBGI stock, buying $21.7 million worth on July 10. The purchase increased his holding in the company by 395,000 shares, making him one of the largest shareholders in Sinclair.This insider purchase came just one day before five-star analyst Daniel Kurnos, of Benchmark, affirmed his buy rating and $90 price target on the stock. Smith’s purchase, and Kurnos’s review, come after the company publicized Q2 revenue guidance of $721 million – in line with previous estimates, and one month before the August 8 Q2 earnings release. In his note to investors, Kurnos says, “Sinclair completed the RSN-Charter (CHTR) negotiations, that Dish (DISH) remains the biggest "wildcard" for the RSNs, but he is optimistic Sinclair will prevail.” His price target, with its 52% upside for the stock, reflects his optimism.Overall, Sinclair has a strong buy analyst consensus rating, with a unanimous 5 buys over the past three months. Shares are selling for $59, and the $69 average price target indicates an 18% upside potential.>>Click Here to see the full list of Analyst Ratings Eidos Therapeutics, Inc. (EIDX)Biotech offers great opportunity it any company able to find a solid niche. Eidos Therapeutics focuses on developing new treatments for the two forms of transthyretin (TTR) amyloidosis (ATTR) disease. While the two disease forms – cardiomyopathy and polyneuropathy – manifest differently, they share the same cause. Eidos is working on a drug, AG10, designed to stabilize the malformed protein (TTR) that causes ATTR disease.Research of this type requires a great deal of capital, and that can be raised through stock sales. Recently, on July 8, Eidos received a capital infusion greater than $100 million, when four major stock owners increased their holdings. BridgeBio Pharma, the parent company of Eidos, along with three top company officers – Neil Kumar, CEO, and Ali Satvat and Eric Aguiar, both on the Board of Directors – all purchased $26.3 million worth of EIDX common shares. The transactions brought the total corporate insider purchases of EIDX in the last three months to $218.35 million – a clear vote of confidence by company officers in Eidos’ research pipeline and future prospects.Their optimism is borne out by a recent analyst review. Yasmeen Rahimi, of Roth Capital, believes “Eidos Therapeutics to maintain and even expedite enrollment into its Phase 3 ATTRibute-CM trial.” She also notes “an increase in AG10's annual price from $150,000 to $225,000 and Probability of Success adjustment from 70% to 80%.” In line with the upbeat prospects for the drug, she boosted her price target on EIDX by 45%, from $28 to $51. Her new price target suggests an upside potential of 27% for the stock.In the last three months, Eidos as received 2 buy ratings, giving it a moderate buy from the analyst consensus. The average price target of $44.50 suggests an 11% upside from the current share price of $39.97.>>Click Here to see the full list of Analyst Ratings Beacon Roofing Supply, Inc. (BECN)Economic experts predict that the US housing market, which has shown a slowing trend since 2017, will continue to weaken into 2020. Slowing population growth, combined with lower incomes and higher debt levels among the millennial age cohort, are putting downward pressure on housing starts.But there is always some demand for new housing, and construction companies like Beacon Roofing, North America’s largest supplier of roofing products to the residential and commercial construction sectors, will always have customers. This optimistic outlook is borne out by Cd&R Investment Associates IX recent purchase, back on June 28, of $158 million worth of BECN stock. A purchase of this size, by an investment group, is a clear signal of confidence in the stock.A look at the analyst reviews will help to explain the confidence. SunTrust’s Keith Hughes said, on March 26, “that while adverse weather factors reduced expectations, the outlook for the rest of the year suggests minimal impact in future quarters. [R]oofing can actually see benefits from weather factors over the medium term as replacement demand rises.” Hughes set a price target of $44, suggesting an upside of 18%.Weighing in just last month, Raymond James analyst Sam Darkatsh concurred on the buy rating, and gave BECN a $40 price target.BECN’s analyst consensus rating is a moderate buy, with 1 buy and 2 hold ratings given in the last 90 days. Shares are selling for $37.20, so the average price target of $40 indicates a possible 7.5% upside.>>Click Here to see the full list of Analyst RatingsVisit TipRanks’ Insiders’ Hot Stocks, and find your own best investment.

  • Is Eidos Therapeutics, Inc. (NASDAQ:EIDX) Trading At A 34% Discount?
    Simply Wall St.

    Is Eidos Therapeutics, Inc. (NASDAQ:EIDX) Trading At A 34% Discount?

    Does the July share price for Eidos Therapeutics, Inc. (NASDAQ:EIDX) reflect what it's really worth? Today, we will...

  • Are Investors Undervaluing Eidos Therapeutics, Inc. (NASDAQ:EIDX) By 34%?
    Simply Wall St.

    Are Investors Undervaluing Eidos Therapeutics, Inc. (NASDAQ:EIDX) By 34%?

    Does the July share price for Eidos Therapeutics, Inc. (NASDAQ:EIDX) reflect what it's really worth? Today, we will...

  • GlobeNewswire

    Eidos Therapeutics to Present at the 2019 BMO Prescriptions for Success Healthcare Conference

    Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management will participate in a fireside chat at the 2019 BMO Prescriptions for Success Healthcare Conference on Tuesday, June 25th at 2:40 p.m. EDT in New York, NY. AG10 is an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin, or TTR, thereby halting at its outset the series of molecular events that give rise to amyloidosis, or ATTR. In a Phase 2 clinical trial in subjects with symptomatic ATTR-CM, AG10 was generally well tolerated, demonstrated 90% average TTR stabilization at day 28, and increased serum TTR concentrations, a prognostic indicator of survival in a retrospective study of ATTR-CM patients, in a dose-dependent manner.

  • GuruFocus.com

    Weekly CEO Buys Highlight

    Details the CEO buys this past week for the following companies: Eidos Therapeutics, Intrexon, AGNC Investment, Rattler Midstream and Discovery

  • Gene Therapy Parent BridgeBio Set to Go Public
    GuruFocus.com

    Gene Therapy Parent BridgeBio Set to Go Public

    Conglomerate has 15 drug development programs at companies under its wing

  • Did Hedge Funds Drop The Ball On Eidos Therapeutics, Inc. (EIDX) ?
    Insider Monkey

    Did Hedge Funds Drop The Ball On Eidos Therapeutics, Inc. (EIDX) ?

    Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips on the charts, usually don't make them change their opinion towards a company. This time it may be different. During the fourth quarter of 2018 we observed increased volatility and small-cap stocks underperformed the market. Hedge […]